Navigation Links
CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
Date:6/25/2008

BRANFORD, Conn., June 25 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study.

The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received prior therapy. This study will enroll up to approximately 40 patients to confirm the maximum tolerated dose (MTD) in this population and to assess efficacy using a Simon 2-Stage design with an endpoint of progression-free rate at 12 weeks. The principal investigator is Dr. Linda Vahdat, Medical Director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, NewYork-Presbyterian Hospital/Weill Cornell.

"We believe that GPNMB is a promising target in breast cancer, and we look forward to better understanding how CR011-vcMMAE could be used in the treatment of this disease," commented Dr. Timothy Shannon, President and Chief Executive Officer of CuraGen Corporation. "We are confident in our ability to continue the rapid development of this program and look forward to providing updated CR011-vcMMAE results for the treatment of melanoma by the end of 2008 and the presentation of preliminary results from this newly initiated study in breast cancer during the first half of 2009."

CR011-vcMMAE targets a protein known as glycoprotein NMB (GPNMB), which is overexpressed in a variety of cancers including breast cancer, melanoma, and brain tumors. CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against GPNMB linked
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014  Neuland Laboratories ... active pharmaceutical ingredients (APIs), complex intermediates ... located in 85 countries, today announced financial results ... 2015, ended June 30, 2014. "Neuland,s ... work flow re-prioritization to accommodate certain customer needs, ...
(Date:8/1/2014)... 1, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Deep ... Industry" and "2014 Deep Research Report on Global ... its research database. Photo - ... Research Report on Global and China Potassium Nitrate ... on China and Global ...
(Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
Breaking Medicine Technology:Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 2Neuland Labs Reports First Quarter Fiscal Year 2015 Financial Results 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 2Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 3Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 4Potassium Nitrate Market & Tricalcium Phosphate Industry Analysis for Global & China Regions 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30
... ADA,s 2009 Convention -- When Shawnae Jebbia won the Miss ... fairytale career. She appeared at events throughout the world, worked ... Shawnae,s world unexpectedly changed when she was diagnosed with hearing ... she had a difficult time understanding and accepting the sudden ...
... Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) today announced ... , Sales in local currency declined by 12% in ... negative currency impact. , Net earnings per diluted ... third quarter of 2008. Adjusted EPS was $1.36, a 6% ...
Cached Medicine Technology:Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:8/1/2014)... (HealthDay News) -- The U.S. Food and Drug Administration ... Jardiance, to help fight type 2 diabetes. ... existing treatment regimens to control blood sugar levels in ... of the Office of Drug Evaluation II in the ... an agency statement. The FDA also recommended that ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 As ... on behalf of women who allegedly experienced the spread ... morcellators in gynecological surgeries, Bernstein Liebhard LLP notes the ... a number of power morcellators marketed by its Ethicon, ... from The New York Times, some critics of the ...
(Date:8/1/2014)... 2014 As AndroGel lawsuits and testosterone ... E. Johnson, Jr. has been appointed as co-lead counsel ... testosterone medications. Since the Fall of 2013, Ron and ... diligently to investigate and prosecute the claims of men ... clots as a result of taking testosterone. As a ...
(Date:8/1/2014)... The American Telemedicine Association (ATA) ... and Peter Welch (D-VT), for their latest actions ... Act of 2014, which improves telemedicine coverage in ... improve healthcare access and affordability using telecommunications technology," ... "These cost-saving provisions are critical to improve telehealth ...
(Date:8/1/2014)... Hot off the presses after the announcement of ... World’s Best Awards by Travel + Leisure , The ... Relaxation Day (technically August 15). , The Lodge at ... help guests celebrate relaxation throughout the month of August. ... wellness to carve out time to relax and unwind. ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
... than 500 Workers, WASHINGTON, May 16 ... the Greater Portland, Oregon and,Vancouver, Washington area have ... are pleased that these workers are now covered ... and a secure retirement,future," said Teamsters General President ...
... fibroids located just beneath the lining of the uterus (submucosal) ... uterine artery embolization (UAE) but usually dont cause major complications, ... 49 patients with 140 fibroids who underwent an MRI examination ... these were submucosal. Of these, 33% migrated to the endometrial ...
... Kwon Presents Urban Health Institute with 10,000 Sensual O Condom ... Mansion Fundraiser, LOS ANGELES, May 16 On Saturday, ... known best for his hit song "Everybody in the Club,Gettin, ... Sensual O Vibrating Condom Packs worth over $50,000. The donation ...
... May 16 Huntsworth plc (LSE: HNT), "the Group",a leading international public relations and healthcare ... the first quarter 2008 (the period,ending March 31, 2008)., The statement follows below., ... ... Interim Management Statement, ...
... Nationwide,Health Properties, Inc. (NYSE: NHP ) announced ... Vice President and Senior Investment Officer. "Dave,has made ... several years as,evidenced by our strong investment growth ... over $1 billion in accretive,investments for NHP, leveraging ...
... for at least a year or two, , , FRIDAY, ... people with type 1 diabetes live insulin-free for at ... longer-term improved metabolic control even after people have to ... glucose monitoring systems, researchers from the University of Miami ...
Cached Medicine News:Health News:Everybody in the Club Scream O! 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:David M. Boitano Promoted to Senior Vice President 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 2Health News:Islet Cell Transplants Aid Type 1 Diabetics 3
Scleral blades designed for trabeculectomy and groove type incisions, scleral standard USA size....
Fechtner Trabeculectomy Marker...
... for Nystagmus when rotated at 8-10 ... 8" diameter. Light weight drum of ... effortless spin mechanism. For use 24 ... both Adult and Pediatric Drums that ...
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Medicine Products: